Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

Dured Dardari (1, 2) , Claire Thomas (2) , Francois-Xavier Laborne (3) , Caroline Tourte , Elodie Henry (4) , Megane Erblang (2) , Stéphanie Bourdon (2) , Alfred Penfornis (3) , Philippe Lopes (5, 5, 6, 7)

1 CH Sud Francilien - Centre Hospitalier Sud Francilien [Corbeil-Essonnes]
2 LBEPS - Laboratoire de Biologie de l'Exercice pour la Performance et la Santé
3 Centre Hospitalier Sud Francilien
4 Hôpital Tarnier
5 STAPS - UEVE - Département Sciences et Techniques des Activités Physiques et Sportives (Evry)
6 UEL - University of East London
7 University of Brighton

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]

Dured Dardari, Claire Thomas, Francois-Xavier Laborne, Caroline Tourte, Elodie Henry, et al.. Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study. Medicina, 2022, 58 (4), pp.555. ⟨10.3390/medicina58040555⟩. ⟨hal-04518574⟩